Participated · Seed · Mar 2026

Founded in 2022 by Omar Dekkiche and Lucie Kriegshauser, PhD, Amatera is developing a high-throughput breeding platform that screens individual plant cells in culture to identify desirable genetic variations before regenerating them into full plants. This approach eliminates the costly and time-consuming step of growing all candidate plants, cutting the development cycle for new varieties of perennial crops such as coffee and wine grapes from decades to a few years. The company induces spontaneous, non-GMO genetic variation and then sequences and analyzes the resulting cell lines with robotics and AI to pinpoint traits like disease resistance, climate resilience, and flavor. Early candidates include a “Robustica” coffee combining Robusta resilience with Arabica taste, a naturally caffeine-free Arabica line, and wine grapes resistant to downy mildew and black rot. Amatera licenses finished varieties for perennial crops while offering its platform to seed companies working on annual row and vegetable crops. Proceeds from its latest funding will help scale the technology and secure additional commercial partnerships.

Participated · Series A · Jan 2026

Evaro is an NHS-licensed digital healthcare platform founded by medical professionals to embed regulated online care within consumer brands’ existing digital experiences. Its healthcare-as-a-service stack covers asynchronous consultations, remote diagnostics, prescribing, dispensing and aftercare, and can be integrated in a short timeframe with minimal engineering lift for partners. The system supports treatment across more than 80 common conditions and has already served over two million patients through various consumer-facing brands. By enabling trusted non-clinical companies to add healthcare offerings, Evaro creates new revenue streams and deeper customer engagement while helping relieve pressure on overstretched UK primary care. The company generates income from these brand partnerships, though detailed revenue figures were not disclosed. With fresh capital in hand, Evaro intends to expand its reach and further develop its infrastructure for the UK market. The new funding round signals investor confidence in the firm’s traction and its ability to scale regulated digital healthcare delivery.

Participated · Seed · Dec 2025

Punto Health is developing a dementia care platform that combines speech-based digital biomarkers with personalized daily care plans and clinician dashboards to shift cognitive care toward earlier identification and proactive, day-to-day support. The system forms a connected ecosystem that guides patients and carers while streamlining monitoring and care coordination for clinicians. Over the past year, the team co-designed and clinically validated the product with partners such as Ace Alzheimer Center Barcelona, several NHS Foundation Trusts, and multiple Spanish hospitals, reaching more than 2,000 individuals in the process. Feedback from these patients, carers, and clinicians has shaped product features aimed at usability and continuous engagement. With fresh seed capital, the company plans to scale its technology, expand hiring in London and Barcelona, and widen access to proactive dementia care for additional families. Financially, Punto Health has secured $2.7 million to fund these growth initiatives. The company is led by co-founder and CEO Anna Muñoz Farré.

Participated · Seed · Oct 2025

Gladys offers an AI-supported marketplace that directly connects people seeking home care with vetted local carers, eliminating traditional agency intermediaries. Its technology automates matching, scheduling, and back-office logistics, which reduces client costs and enables carers to earn up to 65% more than standard agency rates. Since launch, the platform has delivered care across a 20,000 km catchment area and facilitated tens of thousands of hours of independent living support. Co-founded by Georgina Robinson and Alex Sorisi, the company emphasizes fair pay, career development tools for carers, and high-quality support for clients. With fresh seed funding, Gladys plans a nationwide rollout, deployment of additional AI back-office agents, and investment in local care communities. The team aims to provide hundreds of thousands of hours of support by the end of 2026, positioning the business for rapid scale across the UK.

Participated · Seed · Sep 2025

OpenHealth provides an API-driven platform that ingests raw laboratory results from any source and standardizes them into harmonized, AI-ready datasets, plus white-label visualization tools. The product is used by clinics, labs, health and wellness companies to deliver patient-friendly reports, longitudinal insights, and personalised care. The company says it is working toward building the world’s largest usable biomarker database with longitudinal data intended to improve the lives of over 100 million people. Customers include Latin America’s largest diagnostics and hospital groups, fitness and wellness companies such as Smart Fit, healthtech firms like Aware, and a growing network of longevity providers across Europe and the Americas. OpenHealth will use the new funding to accelerate expansion across Europe and to further develop its AI-powered technology for personalised prevention and care. The company is led by CEO and founder Gerrit Glass and is staffed by a European team with clinical, technical, and health system expertise. Financially, OpenHealth closed a $3M seed round and has raised $4.3M in total to date.